Neuropathix, INC.: directors' dealings · United States · SEC (Form 4)

About Neuropathix, INC.

NEUROPATHIX, INC. is a U.S.-listed biopharmaceutical company on the NYSE/NASDAQ market in the United States, focused on discovering and developing novel therapeutics for neuropathic pain, inflammation, and selected neurodegenerative indications. The company’s roots go back to 2010 through Kannalife Sciences, Inc., the original operating vehicle built around cannabinoid-derived science. The current Neuropathix, Inc. entity was incorporated in Delaware in 2013 and later reoriented its business model toward pharmaceutical R&D, with the corporate name change becoming effective in November 2020. Its principal office is in Doylestown, Pennsylvania, United States. At this stage, Neuropathix is best characterized as a preclinical drug-discovery company, meaning its value is driven primarily by pipeline progress, intellectual property, and regulatory milestones rather than commercial sales. The company’s core scientific platform centers on synthetic and phyto-medical cannabinoid derivatives designed to address neuroinflammation, oxidative stress, and mitochondrial dysfunction. Its lead asset, KLS-13019, is presented by the company as a first-in-class, non-opioid, non-NSAID candidate that has been advanced through IND-enabling work and is being studied for chemotherapy-induced peripheral neuropathy (CIPN), neuropathic pain, and opioid use disorder-related applications. Neuropathix also highlights a portfolio of patents and legacy license rights connected to its cannabinoid-based research. In addition, the company has emphasized relationships with recognized scientific and funding partners, including the NIH HEAL Initiative, the Michael J. Fox Foundation, Temple University School of Medicine, and specialized chemistry/manufacturing collaborators. From a competitive standpoint, Neuropathix operates in a niche segment of the biotech market where differentiation depends on mechanistic novelty, proof-of-concept data, and the ability to secure non-dilutive or strategic funding. It is not a broad commercial pharma company; rather, it is an early-stage platform company competing for attention against larger, better-capitalized biopharma groups and other preclinical neuroscience developers. As such, its market positioning is highly event-driven: the share price narrative typically depends on clinical-readout expectations, regulatory submissions, and funding updates. Recent company messaging has focused on advancing KLS-13019 toward the next major inflection point. Neuropathix has indicated that GMP manufacturing, toxicology work, and IND preparation are key near-term priorities, with an FDA IND filing anticipated in 2026, subject to completion of the remaining development package. For investors in France, Belgium, and Switzerland, Neuropathix should be viewed as a speculative U.S. healthcare micro/small-cap on the NYSE/NASDAQ market, with upside tied to pipeline execution and regulatory validation rather than established earnings power.